WallStSmart
ACIU

AC Immune Ltd

NASDAQ: ACIU · HEALTHCARE · BIOTECHNOLOGY

$2.97
-1.33% today

Updated 2026-05-06

Market cap
$303.29M
P/E ratio
P/S ratio
84.88x
EPS (TTM)
$-0.84
Dividend yield
52W range
$2 – $4
Volume
0.3M

AC Immune Ltd (ACIU) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-0.3%
Last 4 quarters
Revenue YoY growth
+13.0%
Most recent quarter
EPS YoY growth
+21.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-0.3%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+7.9%
2025-11-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-04-23$-0.15-7.1%$3.06$2.84-7.2%
2026-03-12$-0.14+10.5%$3.06$3.02-1.5%
2025-11-04$-0.16+15.8%$3.18$3.43+7.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-03-31$-0.14$-0.15-7.1%$1.12M+13.0%
2025-12-31$-0.16$-0.14+10.5%$338000.00-70.3%
2025-09-30$-0.19$-0.16+15.8%$939000.00-96.3%
2025-06-30$-0.17$-0.21-20.6%$1.31M+90.1%
2025-03-31$-0.21$-0.19+8.2%$990000.00+44.1%
2024-12-31$-0.19$-0.16+15.9%$1.14M-92.3%
2024-09-30$-0.23$0.06+126.1%$25.48M
2024-06-30$0.27$-0.23-185.2%$687000.00
2024-03-31$-0.14$-0.18-28.6%$687000.00
2023-12-31$-0.11$-0.05+54.5%$14.80M
2023-09-30$0.03$-0.18-700.0%
2023-06-30$-0.19$-0.20-5.3%

Frequently asked questions

Has AC Immune Ltd beaten earnings estimates?
AC Immune Ltd has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -0.3% over the last 4 quarters.
How does ACIU stock react to earnings?
ACIU stock has moved an average of -0.3% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is AC Immune Ltd's revenue growth rate?
AC Immune Ltd reported year-over-year revenue growth of +13.0% in its most recent quarter, with EPS growing +21.1% year-over-year.